泰格医药 (300347)

Hangzhou Tigermed Consulting Co.,Ltd.

ASZ

Tags

300ESG Index300 Non-Cyclical IndexContract Research Organization (CXO)MSCI Component StocksCSI 200 IndexCSI A100 IndexInnovative DrugsMedical ServicesSTAR and ChiNext 50 IndexContains H-SharesGuozheng Growth IndexGuozheng Services IndexFund Reduction PositionsFund Heavy PositionsLarge Cap GrowthPrivate Enterprises 100 IndexR&DHigh-Performing StocksYangtze River DeltaNon-Cyclical StocksChiNext Large CapChiNext 50 IndexChiNext IndexChiNext HealthcareShenzhen ConnectSZSE 100 IndexSZSE 300 IndexSZSE Growth IndexPharma & BiotechConsumer Services IndexSZSE Medicine Equal Weight IndexBrand Engineering IndexSZSE 100 Equal Weight IndexYangtze River Protection IndexMid-cap High Beta IndexZhongchuang Equal Weight IndexCSI Emerging Industries IndexJuchao Large-cap IndexShenzhen A-Share Pharmaceutical IndexBOC International CSI 300 ESG IndexChiNext Equal Weight IndexCSI All-share Pharmaceutical Sector IndexSZSE Emerging Industries IndexZhongchuang Growth IndexHangzhou Bay Area IndexSZSE 300 Return IndexCSSW Health IndexCSI 1000 Growth IndexSZSE Component Index ReturnCSI 300 Equal Weight IndexCSI 300 ESG IndexLarge & Mid-cap IndexCSWD Life Sciences IndexShanghai-Hong Kong-Shenzhen 300 IndexXingyin Wealth Management Balanced 300 IndexBiomedicine IndexCSSW Silk Road IndexCSI Medical IndexCS Precision Medicine IndexMilitary PartsHuijin ConceptJune 2022 Lock-up ExpiryVenture CapitalPrecision MedicineJune 2021 Lock-up ExpiryCSI 300 Non-cyclical IndexCNI Emerging Industries IndexCS High-end Manufacturing IndexCSI 300 Shenzhen Market IndexZhongchuang 100 Return IndexSTAR Market & ChiNext 50 IndexSZSE Leaders IndexCSI 300 ESG Leading IndexSZSE 100 Return IndexChiNext Quality IndexSHS Innovative Drugs IndexSZSE High Beta IndexCSI 300 Growth IndexSZSE Pharmaceutical IndexCSI 800 IndexCS Pharmaceutical TI Index100 Performance IndexESG 100 IndexCNI Pharmaceutical IndexCSI 1000 Pharmaceutical IndexCNI 300 IndexCCTV 500 IndexCSI 300 USD (CNH) IndexChiNext Basic IndexSZSE Private Enterprises IndexCS Pharmaceutical Innovation IndexSZSE Component Pharmaceutical IndexPharmaceutical Sub-sector IndexCSI All-share Pharmaceutical IndexCSI 300 USD IndexSZSE Pharmaceutical 50 IndexSmart Select 300 ESG Leading IndexSZSE 300 Equal Weight IndexChiNext Low Volatility IndexCSI 800 Pharmaceutical IndexSZSE Component Index Equal WeightPharmaceutical & Health 100 IndexCSI 300 Pharmaceutical IndexCSI 700 IndexMid-small Cap IndexZhongchuang High Beta IndexScientific Research IndexCSI Life Sciences IndexSZSE 200 Return IndexSZSE 200 IndexYangtze River 100 IndexChiNext High Beta IndexCS Innovative Drugs IndexChiNext Growth IndexESG 300 IndexCR New Momentum IndexZhejiang 100 IndexChina Economic Index GDPChiNext Return IndexCS Internet Medical IndexJuchao Mid-cap IndexChiNext Emerging IndexFundamental 600 IndexCS Yangtze River Delta IndexStrategic Emerging Industries 100 IndexZhejiang

K-Line Chart

No K-line data available

Company NameHangzhou Tigermed Consulting Co., Ltd.
Listing Date2012-08-17
Issue Price37.88RMB
Registered Capital86102.60510k RMB
Legal RepresentativeCao Xiaochun
Registered AddressRoom 2001-2010, 20th Floor, Building 8, No. 19 Jugong Road, Xixing Street, Binjiang District, Hangzhou City, Zhejiang Province
IndustryMedical Services
Main BusinessProvides clinical research services for pharmaceutical product development, including Phase I to IV clinical trial technical services, data management, statistical analysis, regulatory submission, etc.
Company ProfileHangzhou Tigermed Consulting Co., Ltd. is a Contract Research Organization (CRO) specializing in providing comprehensive professional services for the entire clinical trial process of new drug development. It has a global service network covering over 60 major cities in mainland China, as well as Hong Kong, Taiwan, South Korea, Japan, Malaysia, Singapore, India, Australia, Canada, the United States, and other regions. With an international professional team of more than 3,200 people, it has successfully conducted over 920 clinical trial services for more than 600 clients worldwide. Tigermed is also known as an 'Innovative CRO' for its participation in clinical trials for more than 130 domestic innovative drugs.

Stock Details

1. Key Indicators

  • Total Shares(W): 86102.61
  • Circulating A-Shares(W): 56621.42
  • Earnings Per Share(RMB): 1.1900
  • Net Assets Per Share(RMB): 24.5943
  • Operating Revenue(W RMB): 502586.83
  • Total Profit(W RMB): 122278.08
  • Net Profit Attributable to Parent(W RMB): 102043.42
  • Net Profit Growth Rate(%): 25.45
  • Weighted Return on Equity(%): 4.8900
  • Operating Cash Flow Per Share(RMB): 0.8590
  • Undistributed Profit Per Share(RMB): 10.9782
  • Capital Reserve Per Share(RMB): 12.3323

2. Main Business

The main business covers:

  • Providing full-process professional services for clinical trials in new drug research and development

3. Company Basic Information

  • Company Name: Hangzhou Tigermed Consulting Co., Ltd.
  • Listing Date: 2012-08-17
  • Industry: Research and Experimental Development
  • Address: 20th Floor, Building 8, No. 19 Jugong Road, Xixing Street, Binjiang District, Hangzhou City, Zhejiang Province, China
  • Website: www.tigermedgrp.com
  • Company Profile: The Company was established through the overall change of Tigermed Co., Ltd. into a joint stock company. On August 4, 2010, the board of directors of Tigermed Co., Ltd. resolved that all shareholders of Tigermed Co., Ltd. would act as promoters, converting the company into a joint stock company based on the audited net assets of Tigermed Co., Ltd. as of May 31, 2010, which amounted to RMB 67,647,753.65, at a ratio of 1:0.5913, resulting in 40,000,000 shares, with the remaining RMB 27,647,753.65 credited to capital reserve. Lixin Certified Public Accountants verified the above capital contribution and issued the “Capital Verification Report” (Xin Hui Shi Bao Zi (2010) No. 11964) on September 15, 2010. On September 8, 2010, the Hangzhou Foreign Trade and Economic Cooperation Bureau issued the “Administrative License Decision on Approving the Change of Hangzhou Tigermed Consulting Co., Ltd.” (Hang Wai Jing Mao Wai Fu Xu [2010] No. 276), approving the overall change of Tigermed Co., Ltd. into a joint stock company. On November 4, 2010, the company completed the industrial and commercial registration change and obtained the business license with registration number 330100400022052. On March 15, 2011, the Hangzhou Foreign Trade and Economic Cooperation Bureau issued the “Filing Form for Non-Substantive Changes to Contracts and Articles of Association of Foreign-Invested Enterprises” (No.: XK-3-2011011), approving the change of the name of the corporate shareholder of Tigermed. On March 17, 2011, Tigermed exchanged for the “Approval Certificate for Enterprises with Investment from Taiwan, Hong Kong, Macao and Overseas Chinese” (Approval No.: Shang Wai Zi Zhe Fu Zi Hang Zi [2008] No. 07448, Serial No.: 3300069691).

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hong Kong Securities Clearing Company Ltd. Northbound Capital 4836.25 8.54
2 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 2885.17 5.10
2 China Europe Healthcare Hybrid Securities Investment Fund Class A Fund 2885.17 5.10
3 HuaBao CSI Healthcare ETF Fund 1456.80 2.57
4 National Social Security Fund Portfolio 601 Social Security Fund 1145.36 2.02
5 E Fund ChiNext ETF Fund 1125.86 1.99
6 Huatai-PineBridge CSI 300 ETF Fund 877.79 1.55
7 China Merchants SSE Bio-medicine Index Fund (LOF) Class A Fund 752.96 1.33
8 Noah Pioneer Hybrid Securities Investment Fund Class A Fund 311.31 0.55
9 Tianhong SSE Bio-medicine ETF Fund 264.22 0.47
10 Tianhong Pharmaceutical Innovation Hybrid Securities Investment Fund Class A Fund 140.78 0.25

5. Concept Sectors

  • H-Share
  • CXO Concept
  • AIGC Concept
  • Innovative Drug
  • AI Healthcare
  • Margin Trading & Securities Lending
  • High-Performance Stock
  • Social Security Fund Heavy Holdings
  • Fund Heavy Holdings
  • MSCI Constituent
  • Fund Reduction
  • Non-Cyclical Stock
  • Zhongchuang 100
  • ChiNext Index
  • SZSE 300
  • CSI 300
  • ChiNext 50
  • Chuangye 300
  • CSI 200
  • 300 Non-Cyclical
  • ChiNext Large Cap
  • Chuang Quality
  • Chuang Healthcare
  • STAR 50
  • 300 ESG

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information